March 7 (Reuters) - Dexcom Inc DXCM.O:
DEXCOM INC - DOES NOT EXPECT MATERIAL IMPACT FROM FDA WARNING LETTER
DEXCOM INC - FDA CITES DEFICIENCIES IN DEXCOM'S RESPONSE LETTERS
DEXCOM INC - FDA OBSERVES NON-CONFORMITIES IN DEXCOM'S MANUFACTURING PROCESSES
DEXCOM INC: ON MARCH 4 RECEIVED WARNING LETTER FROM FDA FOLLOWING INSPECTIONS OF CO’S FACILITIES IN SAN DIEGO, CALIFORNIA, & MESA, ARIZONA
Further company coverage: DXCM.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.